LHPP在恶性肿瘤中的作用

doi:10.3760/cma.j.cn371439-20200630-00080

国际肿瘤学杂志 ›› 2021, Vol. 48 ›› Issue (7): 420-423.doi: 10.3760/cma.j.cn371439-20200630-00080

LHPP在恶性肿瘤中的作用

李田田, 陈敏, 刘怡晨, 彭婕, 施小凤()

江苏大学附属医院血液科,镇江 212000

收稿日期:2020-06-30 修回日期:2020-09-17 出版日期:2021-07-08 发布日期:2021-07-26
通讯作者: 施小凤 E-mail:shixiaofeng1977@163.com
基金资助:
国家自然科学基金(81700130);镇江市科技创新资金(SH2017006)

Role of LHPP in malignant tumor

Li Tiantian, Chen Min, Liu Yichen, Peng Jie, Shi Xiaofeng()

Department of Hematology, Affiliated Hospital of Jiangsu University, Zhenjiang 212000, China

Received:2020-06-30 Revised:2020-09-17 Online:2021-07-08 Published:2021-07-26
Contact: Shi Xiaofeng E-mail:shixiaofeng1977@163.com
Supported by:
National Natural Science Foundation of China(81700130);Science and Technology Innovation Fund Project of Zhenjiang of China(SH2017006)

摘要/Abstract

摘要：

磷酸赖氨酸磷酸组氨酸无机焦磷酸盐磷酸酶(LHPP)是一种从蠕虫到人类进化中高度保守的组氨酸磷酸酶。最近研究表明,LHPP作为一种肿瘤抑制因子,可通过参与多种细胞信号通路和蛋白质磷酸化的调节,抑制肿瘤细胞增殖、生长和迁移,促进凋亡。因此,对LHPP作用机制的深入研究,有助于寻找诊断和预测相关肿瘤的最佳分子标志物及治疗靶点,对于改善相关肿瘤的预后至关重要。

关键词: 肿瘤, 磷酸肌醇3-激酶, 预后, LHPP

Abstract:

Phospholysine phosphohistidine inorganic pyrophosphate phosphatase (LHPP) is a highly conserved histidine phosphatase from worms to humans in evolution. Recent studies have shown that LHPP, as a tumor suppressor, can inhibit the proliferation, growth and migration of the cells and promote apoptosis by participating in the regulation of various cell signaling pathways and protein phosphorylation. Therefore, the deeply study on the mechanism of LHPP is helpful to explore the best diagnostic markers and therapeutic targets for related tumors, which is essential for improving the prognosis of related tumors.

Key words: Neoplasms, Phosphatidylinositol 3-kinase, Prognosis, LHPP

李田田, 陈敏, 刘怡晨, 彭婕, 施小凤. LHPP在恶性肿瘤中的作用[J]. 国际肿瘤学杂志, 2021, 48(7): 420-423.

Li Tiantian, Chen Min, Liu Yichen, Peng Jie, Shi Xiaofeng. Role of LHPP in malignant tumor[J]. Journal of International Oncology, 2021, 48(7): 420-423.

参考文献 28

[1]	赵聪选, 于韬. 胶质瘤相关基因的挖掘及预测[J]. 国际肿瘤学杂志, 2020, 47(5):293-296. DOI: 10.3760/cma.j.cn371439-20200123-00021.
[2]	Hindupur SK, Colombi M, Fuhs SR, et al. The protein histidine phosphatase LHPP is a tumour suppressor[J]. Nature, 2018, 555(7698):678-682. DOI: 10.1038/nature26140. doi: 10.1038/nature26140
[3]	Huang H, Pandya C, Liu C, et al. Panoramic view of a superfamily of phosphatases through substrate profiling[J]. Proc Natl Acad Sci U S A, 2015, 112(16):E1974-E1983. DOI: 10.1073/pnas.1423570112. doi: 10.1073/pnas.1423570112
[4]	Gohla A. Do metabolic HAD phosphatases moonlight as protein phosphatases?[J]. Biochim Biophys Acta Mol Cell Res, 2019, 1866(1):153-166. DOI: 10.1016/j.bbamcr.2018.07.007. doi: 10.1016/j.bbamcr.2018.07.007
[5]	Cui L, Gong X, Tang Y, et al. Relationship between the LHPP gene polymorphism and resting-state brain activity in major depressive disorder[J]. Neural Plast, 2016, 2016:9162590. DOI: 10.1155/2016/9162590.
[6]	Kestler C, Knobloch G, Tessmer I, et al. Chronophin dimerization is required for proper positioning of its substrate specificity loop[J]. J Biol Chem, 2014, 289(5):3094-3103. DOI: 10.1074/jbc.M113.536482. doi: 10.1074/jbc.M113.536482
[7]	Tian Z, Yu T, Wei H, et al. Clinical value of LHPP-associated microRNAs combined with protein induced by vitamin K deficiency or antagonist-Ⅱ in the diagnosis of alpha-fetoprotein-negative hepatocellular carcinoma[J]. J Clin Lab Anal, 2020, 34(2):e23071. DOI: 10.1002/jcla.23071.
[8]	Zheng J, Dai X, Chen H, et al. Down-regulation of LHPP in cervical cancer influences cell proliferation, metastasis and apoptosis by modulating AKT[J]. Biochem Biophys Res Commun, 2018, 503(2):1108-1114. DOI: 10.1016/j.bbrc.2018.06.127. doi: 10.1016/j.bbrc.2018.06.127
[9]	Li Y, Zhang X, Zhou X, et al. LHPP suppresses bladder cancer cell proliferation and growth via inactivating AKT/p65 signaling pathway[J]. Biosci Rep, 2019, 39(7): BSR20182270. DOI: 10.1042/BSR20182270.
[10]	Wu F, Chen Y, Zhu J. LHPP suppresses proliferation, migration, and invasion and promotes apoptosis in pancreatic cancer[J]. Biosci Rep, 2020, 40(3): BSR20194142. DOI: 10.1042/BSR20194142.
[11]	Hou B, Li W, Li J, et al. Tumor suppressor LHPP regulates the proliferation of colorectal cancer cells via the PI3K/AKT pathway[J]. Oncol Rep, 2020, 43(2):536-548. DOI: 10.3892/or.2019.7442.
[12]	Sun W, Qian K, Guo K, et al. LHPP inhibits cell growth and migration and triggers autophagy in papillary thyroid cancer by regulating the AKT/AMPK/mTOR signaling pathway[J]. Acta Biochim Biophys Sin (Shanghai), 2020, 52(4):382-389. DOI: 10.1093/abbs/gmaa015. doi: 10.1093/abbs/gmaa015
[13]	Noorolyai S, Shajari N, Baghbani E, et al. The relation between PI3K/AKT signalling pathway and cancer[J]. Gene, 2019, 698:120-128. DOI: 10.1016/j.gene.2019.02.076. doi: S0378-1119(19)30217-3 pmid: 30849534
[14]	Xiao S, Yang M, Yang H, et al. miR-330-5p targets SPRY2 to promote hepatocellular carcinoma progression via MAPK/ERK signaling[J]. Oncogenesis, 2018, 7(11):90. DOI: 10.1038/s41389-018-0097-8. doi: 10.1038/s41389-018-0097-8
[15]	Zhu Y, Zhou C, He Q. High miR-139-3p expression predicts a better prognosis for hepatocellular carcinoma: a pooled analysis[J]. J Int Med Res, 2019, 47(1):383-390. DOI: 10.1177/0300060518802727. doi: 10.1177/0300060518802727
[16]	Ali HEA, Emam AA, Zeeneldin AA, et al. Circulating miR-26a, miR-106b, miR-107 and miR-133b stratify hepatocellular carcinoma patients according to their response to transarterial chemoembolization[J]. Clin Biochem, 2019, 65:45-52. DOI: 10.1016/j.clinbiochem.2019.01.002. doi: 10.1016/j.clinbiochem.2019.01.002
[17]	Ali HEA, Abdel Hameed R, Effat H, et al. Circulating microRNAs panel as a diagnostic tool for discrimination of HCV-associated hepatocellular carcinoma[J]. Clin Res Hepatol Gastroenterol, 2017, 41(4):e51-e62. DOI: 10.1016/j.clinre.2017.06.004. doi: 10.1016/j.clinre.2017.06.004
[18]	Lee Y, Dominy JE, Choi YJ, et al. Cyclin D1-Cdk4 controls glucose metabolism independently of cell cycle progression[J]. Nature, 2014, 510(7506):547-551. DOI: 10.1038/nature13267. doi: 10.1038/nature13267
[19]	Manning BD, Toker A. AKT/PKB signaling: navigating the network[J]. Cell, 2017, 169(3):381-405. DOI: 10.1016/j.cell.2017.04.001. doi: 10.1016/j.cell.2017.04.001
[20]	Chen CY, Chen J, He L, et al. PTEN: tumor suppressor and metabolic regulator[J]. Front Endocrinol (Lausanne), 2018, 9:338. DOI: 10.3389/fendo.2018.00338. doi: 10.3389/fendo.2018.00338
[21]	Xia P, Xu XY. PI3K/Akt/mTOR signaling pathway in cancer stem cells: from basic research to clinical application[J]. Am J Cancer Res, 2015, 5(5):1602-1609. pmid: 26175931
[22]	司贮元, 周旭, 朱化强, 等. 组氨酸磷酸酶LHPP对胰腺癌预后的影响[J]. 中华实验外科杂志, 2019, 36(8):1472-1474. DOI: 10.3760/cma.j.issn.1001-9030.2019.08.042.
[23]	李德馨, 刘斌, 任飞飞, 等. LHPP在人胃腺癌组织中的表达及意义[J]. 中国微生态学杂志, 2019, 31(5):544-549. DOI: 10.13381/j.cnki.cjm.201905010.
[24]	刘丹. 组氨酸磷酸酶LHPP在非小细胞肺癌中的表达及其临床意义的研究[D]. 沈阳: 中国医科大学, 2020. DOI: 10.27652/d.cnki.gzyku.2020.001364.
[25]	Zhang Q, Xiong M, Liu J, et al. Targeted nanoparticle-mediated LHPP for melanoma treatment[J]. Int J Nanomedicine, 2019, 14:3455-3468. DOI: 10.2147/IJN.S196374. doi: 10.2147/IJN
[26]	Vijayakrishnan J, Kumar R, Henrion MY, et al. A genome-wide association study identifies risk loci for childhood acute lymphoblastic leukemia at 10q26.13 and 12q23.1[J]. Leukemia, 2017, 31(3):573-579. DOI: 10.1038/leu.2016.271. doi: 10.1038/leu.2016.271 pmid: 27694927
[27]	Lesseur C, Diergaarde B, Olshan AF, et al. Genome-wide association analyses identify new susceptibility loci for oral cavity and pharyngeal cancer[J]. Nat Genet, 2016, 48(12):1544-1550. DOI: 10.1038/ng.3685. doi: 10.1038/ng.3685 pmid: 27749845
[28]	Wang Z, McGlynn KA, Rajpert-De Meyts E, et al. Meta-analysis of five genome-wide association studies identifies multiple new loci associated with testicular germ cell tumor[J]. Nat Genet, 2017, 49(7):1141-1147. DOI: 10.1038/ng.3879. doi: 10.1038/ng.3879

LHPP在恶性肿瘤中的作用

Role of LHPP in malignant tumor

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 28

相关文章 15

编辑推荐

Metrics

本文评价

[1]	刘娜, 寇介丽, 杨枫, 刘桃桃, 李丹萍, 韩君蕊, 杨立洲. 血清miR-106b-5p、miR-760联合低剂量螺旋CT诊断早期肺癌的临床价值[J]. 国际肿瘤学杂志, 2024, 51(6): 321-325.
[2]	钱晓涛, 石子宜, 胡格, 吴晓维. Ⅲ~ⅣA期食管鳞状细胞癌放化疗后行巩固化疗的疗效：一项真实世界临床研究[J]. 国际肿瘤学杂志, 2024, 51(6): 326-331.
[3]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊. 局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[4]	袁健, 黄燕华. Hp-IgG抗体联合血清DKK1、sB7-H3对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(6): 338-343.
[5]	陈红健, 张素青. 血清miR-24-3p、H2AFX与肝癌患者临床病理特征及术后复发的关系研究[J]. 国际肿瘤学杂志, 2024, 51(6): 344-349.
[6]	郭泽浩, 张俊旺. PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.
[7]	张百红, 岳红云. 新作用机制的抗肿瘤药物进展[J]. 国际肿瘤学杂志, 2024, 51(6): 354-358.
[8]	许凤琳, 吴刚. EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[9]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[10]	张蕊, 褚衍六. 基于FIT与肠道菌群的结直肠癌风险评估模型的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 370-375.
[11]	高凡, 王萍, 杜超, 褚衍六. 肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[12]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东. ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[13]	范志鹏, 余静, 胡静, 廖正凯, 徐禹, 欧阳雯, 谢丛华. 炎症标志物的变化趋势对一线接受免疫联合化疗的晚期非小细胞肺癌患者预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(5): 257-266.
[14]	刘静, 刘芹, 黄梅. 基于SMOTE算法的食管癌放化疗患者肺部感染的预后模型构建[J]. 国际肿瘤学杂志, 2024, 51(5): 267-273.
[15]	杨琳, 路宁, 温华, 张明鑫, 朱琳. 炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.